All In Biotech

Drug Trial Radar · NCT04716114

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

A Phase 3, Open-Label, Multicenter, Randomized Study of SKLB1028 Versus Salvage Chemotherapy in Patients With FLT3-mutated Acute Myeloid Leukemia Refractory to or Relapsed After First-line Treatment(ALIVE)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 315 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

315

Planned (sponsor's estimate)

Start

Mar 24, 2021

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized,multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia(AML)compared to salvage chemotherapy.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • SKLB1028Drug

    SKLB1028 will be administered by oral capsules, 150 mg twice daily (BID).

  • Salvage ChemotherapyDrug

    Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) will be administered by subcutaneous (SC) and/or intravenous (IV) injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Interim analysis: CR/CRh rate in the experimental group.Time frame: up to 4 years.
  2. The final analysis: Overall Survival(OS)Time frame: up to 4 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.